Prescription drug · ANDA
Acamprosate Calcium NDC 69452-353
Acamprosate calcium 333 mg/1 · Tablet, Delayed release · Oral · Bionpharma Inc.,
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 69452-353-25 | 69452035325 | 180 TABLET, DELAYED RELEASE in 1 BOTTLE (69452-353-25)Marketed from Dec 1, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Acamprosate Calcium
- Generic name (nonproprietary)
- acamprosate calcium
- Active ingredients
- Acamprosate calcium — 333 mg/1
- Dosage form
- Tablet, Delayed release
- Route
- Oral
- Labeler
- Bionpharma Inc.,NDC labeler code 69452
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219904
- Marketing start
- Listing expires
- Identifiers
- Product ID 69452-353_44732224-b730-9a24-e063-6394a90ac0c0SPL ID 44732224-b730-9a24-e063-6394a90ac0c0SPL set ID 4473326f-79f1-61b2-e063-6294a90a17a3RxCUI 835726UNII 59375N1D0U
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N469452035325followed by a unit qualifier and the quantityPackage 69452-0353-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol i…
Excerpt only. Read the full label for complete information.
About NDC 69452-353
- What is NDC 69452-353?
- 69452-353 is the product NDC for Acamprosate Calcium, Acamprosate calcium 333 mg/1 tablet, delayed release, listed with the FDA by Bionpharma Inc.,. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Acamprosate Calcium.
- What is the active ingredient?
- Acamprosate calcium.
- Who is the labeler?
- Bionpharma Inc.,, NDC labeler code 69452. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Acamprosate Calcium?
- 10 other product NDCs are listed under this name. See all Acamprosate Calcium NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Acamprosate Calcium products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Somerset Therapeutics, LLC | 70069-860 | 70069-0860-1870069-0860-30 |
| acamprosate calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | REMEDYREPACK INC. | 70518-4616 | 70518-4616-00 |
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8660 | 00615-8660-39 |
| acamprosate calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Zydus Pharmaceuticals (USA) Inc. | 68382-569 | 68382-0569-0168382-0569-0568382-0569-06+3 more |
| acamprosate calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Zydus Lifesciences Limited | 70771-1057 | 70771-1057-0070771-1057-0170771-1057-03+3 more |
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | American Health Packaging | 60687-121 | 60687-0121-25 |
| Acamprosate Calciumacamprosate calcium enteric-coated | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Mylan Pharmaceuticals Inc. | 0378-6333 | 00378-6333-80 |
| Acamprosate Calciumacamprosate calcium enteric-coated | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8560 | 00615-8560-39 |
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Major Pharmaceuticals | 0904-7213 | 00904-7213-04 |
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | Glenmark Pharmaceuticals Inc., USA | 68462-435 | 68462-0435-1168462-0435-18 |
Other NDCs under ANDA 219904
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Acamprosate Calcium | Acamprosate calcium 333 mg/1 | Tablet, Delayed releaseOral | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8660 |